ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVO Stock Price » NVO Stock News

Novo Nordisk a S Share News

 Novo-nordisk a/s (denmark) Stock Price
NVO Stock Price
 Novo-nordisk a/s (denmark) Stock Chart
NVO Stock Chart
 Novo-nordisk a/s (denmark) Stock News
NVO Stock News
 Novo-nordisk a/s (denmark) Company Information
NVO Company Information
 Novo-nordisk a/s (denmark) Stock Trades
NVO Stock Trades

Novo Nordisk May Perform Stock Split - Chief Financial Officer

COPENHAGEN -(Dow Jones)- Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) may perform a stock split in the next couple of years, the company's chief financial officer Jesper Brandgaard said Thursday. "We have done several stock splits over the years, when the price has risen to levels that we found too high. With a price of more than $100, it is something we will consider again," Brandgaard said, speaking after the company released its fourth-quarter results. Novo Nordisk, the world's largest maker of insulin, earlier Thursday reported that its net profit rose 19% on the year in the fourth quarter, to 4.69 billion Danish kroner ($829 million). The result was better than expected, helped by strong growth in sales of its GLP-1 diabetes drug Victoza and ultra-long acting insulin Levemir. -By Flemming Emil Hansen and Niclas Rolander, Dow Jones Newswires; +46-8-5451-3102;

Stock News for Novo Nordisk a S (NVO)
07/25/201607:37:33Report of Foreign Issuer (6-k)
07/18/201610:55:33Report of Foreign Issuer (6-k)
07/18/201608:30:15Report of Foreign Issuer (6-k)
07/05/201606:03:12Report of Foreign Issuer (6-k)
07/01/201615:09:19Report of Foreign Issuer (6-k)
06/27/201611:12:50Report of Foreign Issuer (6-k)
06/20/201607:53:43Report of Foreign Issuer (6-k)
06/14/201618:05:00ADRs End Lower; Novo Nordisk Falls
06/14/201607:00:00Dans l'étude LEADER, Victoza® a considérablement réduit le ris...
06/13/201620:52:00Study Finds Victoza® Significantly Reduced the Risk of Heart...
06/13/201612:41:00L'insuline asparte à action ultra-rapide entraîne une réduction st...
06/13/201612:40:00Faster-acting insulin aspart showed a statistically significant...
06/13/201610:18:39Report of Foreign Issuer (6-k)
06/08/201606:07:17Report of Foreign Issuer (6-k)
05/31/201606:52:49Report of Foreign Issuer (6-k)
05/27/201607:17:31Specialized Disclosure Report (sd)
05/25/201606:11:46Report of Foreign Issuer (6-k)
05/20/201609:22:59Report of Foreign Issuer (6-k)
05/20/201607:54:07Report of Foreign Issuer (6-k)
05/16/201611:43:50Report of Foreign Issuer (6-k)

Novo Nordisk a S and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations